Abstract
The incorporation of novel agents (bortezomib, thalidomide and lenalidomide) in the treatment of newly diagnosed, non-transplant eligible symptomatic multiple myeloma (MM) patients (pts) improves their clinical outcomes. During the last decade, the Italian Regulatory Drug Agency AIFA approved as 1° line treatments the following: thalidomide-melphalan-prednisone (TMP), bortezomib-melphalan-prednisone (VMP) and lenalidomide-dexamethasone (Rd). Since December 2016 all of these treatments became available in Italy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
